Determining accurate vancomycin MIC values for methicillin-resistant Staphylococcus aureus by the microdilution...

Area of Science:

• Microbiology
• Pharmacokinetics
• Mathematical Modeling

Background:

• Accurate determination of vancomycin Minimum Inhibitory Concentration (MIC) is critical for treating methicillin-resistant Staphylococcus aureus (MRSA) infections.
• The standard broth microdilution method's variability can impact vancomycin therapeutic efficacy, defined by the AUC(0-24)/MIC ratio.
• Understanding MIC variability is essential for optimizing vancomycin dosing strategies.

Purpose of the Study:

• To develop a modified Gompertz function model for accurate vancomycin MIC determination in MRSA.
• To evaluate the impact of modeled MIC values on the vancomycin therapeutic target (AUC(0-24)/MIC ≥ 400).

Main Methods:

• Utilized three clinical MRSA isolates with varying vancomycin MICs.
• Modeled optical density data using non-linear regression and the Gompertz equation to derive MIC values.
• Employed Monte Carlo simulation to calculate mean vancomycin AUC(0-24) based on established pharmacokinetic data.

Main Results:

• Modeled MIC values were generally lower than those obtained by the Etest diffusion method.
• The AUC(0-24)/MIC ratio remained unaffected for strains with Etest MICs of 1 mg/L.
• Confidence intervals for the AUC(0-24)/MIC ratio included values below 400 for strains with Etest MICs >1 mg/L.

Conclusions:

• Inherent variability in the broth microdilution method may explain differing clinical outcomes in vancomycin-treated MRSA patients.
• Strains with Etest MICs of 1.5-2 mg/L, corresponding to modeled MICs of 0.84-1.52 mg/L, may be particularly affected.
• Accurate MIC determination is crucial for achieving the vancomycin therapeutic target in MRSA infections.